South African SARS-CoV-2 Variant Alarms Scientists
South African SARS-CoV-2 Variant Alarms Scientists
An additional mutation in the spike protein of the coronavirus may help it elude antibody recognition, and scientists are investigating if current vaccines will protect against it.
South African SARS-CoV-2 Variant Alarms Scientists
South African SARS-CoV-2 Variant Alarms Scientists

An additional mutation in the spike protein of the coronavirus may help it elude antibody recognition, and scientists are investigating if current vaccines will protect against it.

An additional mutation in the spike protein of the coronavirus may help it elude antibody recognition, and scientists are investigating if current vaccines will protect against it.

vaccination
Introducing Inoculation, 1721
Introducing Inoculation, 1721
Max Kozlov | Jan 1, 2021
As a deadly smallpox outbreak ravaged Boston, one of the city’s leaders advocated for a preventive measure he’d learned about from Onesimus, an enslaved man.
An End in Sight
An End in Sight
Bob Grant | Jan 1, 2021
Last year humanity confronted our biggest challenge in a century. Science helped us see the light at the end of the tunnel. But we need to keep moving forward to emerge.
Ten Minute Sabbatical
Ten Minute Sabbatical
The Scientist Staff | Jan 1, 2021
Take a break from the bench to puzzle and peruse.
Immunity to SARS-CoV-2 Lasts at Least Six Months, Data Show
Immunity to SARS-CoV-2 Lasts at Least Six Months, Data Show
Ashley Yeager | Nov 23, 2020
Half a year after infection, people who had recovered from COVID-19 had robust antibodies, along with traces of the virus in their gut, which may drive long-lasting immunity.
Moderna’s COVID-19 Vaccine 94 Percent Effective: Initial Data
Moderna’s COVID-19 Vaccine 94 Percent Effective: Initial Data
Max Kozlov | Nov 16, 2020
The results mark the second experimental COVID-19 vaccine to show high efficacy, but the study is not complete and the data have not been peer reviewed.
Updated
Pfizer’s COVID-19 Vaccine 90 Percent Effective: Initial Data
Pfizer’s COVID-19 Vaccine 90 Percent Effective: Initial Data
Max Kozlov | Nov 9, 2020
Vaccine experts say the results surpass their expectations, but the study is not complete, and the data have not been peer reviewed.
Contributors
Contributors
The Scientist Staff | Nov 1, 2020
Meet some of the people featured in the November 2020 issue of The Scientist.
Infographic: How Vaccines Train Innate Immunity
Infographic: How Vaccines Train Innate Immunity
Shawna Williams | Nov 1, 2020
A recent study elucidates some of the changes that occur in the body after inoculation with a tuberculosis vaccine.
How Some Vaccines Protect Against More than Their Targets
How Some Vaccines Protect Against More than Their Targets
Shawna Williams | Nov 1, 2020
As researchers test existing vaccines for nonspecific protection against COVID-19, immunologists are working to understand how some inoculations protect against pathogens they weren’t designed to fend off.